Abstract: The disclosure relates to compositions for inhibiting bacterial conjugation or horizontal plasmid-associated gene transfer. The compositions may comprise short chain fatty acids. The compositions may also comprise short chain fatty acid-producing probiotic bacteria. Also disclosed herein are methods of inhibiting bacterial conjugation or horizontal gene transfer in the gut of a subject.

Abstract: An artificial and/or simulated environment is used to raise a domestic or commercially raised animal to promote a positive health feedback and to minimize stress on the animal. The simulated environment is used to create the façade of a free range or cage free environment, while also minimizing the exposure to inclement weather, potential predators, and other unknown or stress-inducing situations. The results include animals that have higher resistance to diseases and have a lower stress. The artificial environment can be created by projecting or otherwise showing images and/or videos depicting simulation of environments, climate, and/or other unknown situations to normalize the animals to the same.

Abstract: The present invention relates to probiotic compositions and methods of using such compositions. In particular, the present invention provides method of using segmented filamentous bacteria to improve gastrointestinal health, reduce bacterial pathogens, and stimulate host immune function in poultry.

Abstract: The present invention encompasses recombinant bacteria suitable for live attenuated vaccines, and methods of use thereof. One aspect of the present invention encompasses a recombinant Salmonella bacterium. The bacterium comprises a first promoter operably linked to a nucleic acid encoding a toxin and a second promoter operably linked to a nucleic acid encoding an antitoxin, wherein the second promoter is inactive in vivo, but active in vitro.

Abstract: The present invention encompasses recombinant bacteria suitable for live attenuated vaccines, and methods of use thereof. One aspect of the present invention encompasses a recombinant Salmonella bacterium. The bacterium comprises a first promoter operably linked to a nucleic acid encoding a toxin and a second promoter operably linked to a nucleic acid encoding an antitoxin, wherein the second promoter is inactive in vivo, but active in vitro.

Abstract: The present invention relates to a recombinant bacterium that is capable of eliciting an immune response against at least two enteric pathogens, without substantially inducing an immune response specific to the serotype of the bacterium. The invention also relates to methods of making such a bacterium and vaccines and methods of using such a bacterium.

Abstract: The present invention relates to a recombinant bacterium that is capable of eliciting an immune response against at least two enteric pathogens, without substantially inducing an immune response specific to the serotype of the bacterium. The invention also relates to methods of making such a bacterium and vaccines and methods of using such a bacterium.